DF
CRSP icon

Dunhill Financial’s CRISPR Therapeutics CRSP Stock Holding History

Dunhill Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32
Closed -$1.09K – 1021
2025
Q1 		$1.09K Hold
32
– – ﹤0.01% 797
2024
Q4 		$1.26K Hold
32
– – ﹤0.01% 743
2024
Q3 		$1.5K Hold
32
– – ﹤0.01% 757
2024
Q2 		$1.73K Hold
32
– – ﹤0.01% 592
2024
Q1 		$2.18K Hold
32
– – ﹤0.01% 476
2023
Q4 		$2K Buy
+32
New +$1.77K ﹤0.01% 457

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dunhill Financial's CRSP Position: Q2 2025 in Review

Dunhill Financial sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 32 shares — an estimated $1.09K sold.

Dunhill Financial first reported a position in CRSP in Q4 2023 and held it in 6 quarters. The position peaked at $2.18K in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Dunhill Financial reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Dunhill Financial sold 32 CRISPR Therapeutics shares in Q2 2025, an estimated $1.09K.
  • Dunhill Financial first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 6 quarters.
  • Dunhill Financial's CRISPR Therapeutics position peaked at $2.18K in Q1 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Dunhill Financial's 13F filing for Q2 2025, filed 5 Aug 2025.